Grant H. Skrepnek, Ph.D., R.Ph.

---

Summary

I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.

---

Research

Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.

---

Publications & Presentations

91. Harshman R S, Richerson G T, Hadker N, Greene B L, Brown T M, Foster T S, Turner B H, Skrepnek S H, Doyle J J. Impact of a hypertension management/health promotion program on commercial driver's license employees of a self-insured utility company. Journal of occupational and environmental medicine. 2008; 50 : 359-65

92. Wang M T, Skrepnek G H, Armstrong E, Sherrill D L, Harris R B, Tsai C L, Malone D C. Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma. Current medical research and opinion. 2008; 24 : 859-67

93. Ko Y, Malone D C, Skrepnek G H, Armstrong E P, Murphy J E, Abarca J, Rehfeld R A, Reel S J, Woosley R L. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug safety. 2008; 31 : 525-36

94. Grizzle A J, Mahmood M H, Ko Y, Murphy J E, Armstrong E P, Skrepnek G H, Jones W N, Schepers G P, Nichol W P, Houranieh A, Dare D C, Hoey C T, Malone D C. Reasons provided by prescribers when overriding drug-drug interaction alerts. The American journal of managed care. 2007; 13 : 573-8

95. Mahmood M, Malone D C, Skrepnek G H, Abarca J, Armstrong E P, Murphy J E, Grizzle A J, Ko Y, Woosley R L. Potential drug-drug interactions within Veterans Affairs medical centers. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2007; 64 : 1500-5

Grants

1. [Cooperative Agreement] Oklahoma State Department of Health, A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes – 2023 (DP-23-0020, FAIN #NU58DP007376, CFDA #93.988 (Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems). . CDC. Start Date: 2023. End Date: 2024.

2. [Cooperative Agreement] Oklahoma State Department of Health, Chronic Disease Prevention Program: The National Cardiovascular Health Program (DP-23-0004, FAIN #NU58DP007471, CFDA #93.426 - The National Cardiovascular Health Program, CDV/Heart. CDC. Start Date: 2023. End Date: 2024.

3. HIV Adherence Services. Start Date: 2022. End Date: 2023.

4. Patterns of Care, Outcomes, and Barriers to Treatment Success or Vaccination Associated with Adult Community-Acquired Pneumonia in Medicaid. Misc Non-Federal. Start Date: 2021. End Date: 2022.

5. [Service Agreement] Opioid Use Under Oklahoma Senate Bill 848.. Non-federal. Start Date: 2020. End Date: 2020.

Awards and Honors

no results

Education

no results

Administrative Assignments

1. Role: Director. Scope: Department. Date: 2019.

Read More

2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.

Read More